Introduction {#Sec1}
============

Chronic obstructive pulmonary disease (COPD) is an obstructive airway disease with both overlapping and distinctive features as with asthma^[@CR1]^. Asthma is characterized by eosinophilic inflammation^[@CR2]^, whereas COPD is predominantly associated with neutrophilic inflammation in the airways^[@CR3]^. Growing evidence suggested that neither characteristic was immutably ingrained in either disease. This difference in cellular composition of induced sputum may, if ever, be indistinguishable between these disease groups^[@CR2]^. Increased sputum eosinophils has been reported in both stable^[@CR3]^ and exacerbation phase^[@CR4]^ of patients with COPD, implying the potential role of eosinophils in the pathogenesis of COPD^[@CR2]^.

Eosinophilia is generally defined as greater or equal to 2% eosinophils in either blood or sputum^[@CR3],[@CR5]--[@CR7]^. Alternatively, an absolute blood eosinophil count of 0.34 × 10^9^ cells per liter can be used as a threshold for risk stratification^[@CR7]^. Peripheral blood eosinophil count is highly associated with eosinophilia of the respiratory tract^[@CR5]^. This blood biomarker has also been shown to reflect submucosal eosinophilia of the lung and reticular basement membrane thickening^[@CR8]^. Given this context, we considered that patients with COPD who had more than 2% of eosinophils, either in the blood or sputum, as eosinophilic COPD.

Acute exacerbation of COPD significantly increases symptoms, deteriorates pulmonary function, increases rate of hospitalization and lengthens hospital stay further impairing functional capacity and quality of life (QOL) imposing additional burden to healthcare system^[@CR9]--[@CR11]^. The in-hospital mortality can reach 30% or more^[@CR12]^. Seeking for predictive biomarkers for clinical outcome in this population is thus of high priority.

Numerous studies have evaluated eosinophilia in relation to exacerbation risk^[@CR5],[@CR7],[@CR13]^, length of hospital stay^[@CR14]--[@CR16]^, in-hospital mortality^[@CR12],[@CR17],[@CR18]^, and response to steroidal and bronchodilator therapies^[@CR9]--[@CR11]^ but the evidence is conflicting. Some studies have reported a higher risk for exacerbation in patients with eosinophilic COPD^[@CR13],[@CR19]^. Conversely, a retrospective study suggested that a higher level of eosinophils protected against disease aggravation^[@CR16]^. Other research teams failed to detect any association^[@CR5],[@CR7],[@CR20]^.

We conducted a systematic review and meta-analysis of clinical outcome measures comparing patients with COPD who had eosinophilia and those without eosinophilia.

Results {#Sec2}
=======

Of 3,131 abstracts identified by the initial search, 1,710 and 1,323 articles were removed, respectively, because of irrelevance or overlaps. After exclusion, 37 studies involving 99,122 patients published between 1998 and 2016 were included for qualitative synthesis (Fig. [1](#Fig1){ref-type="fig"}). Of these, 14 studies were included in meta-analysis. The number of entries derived from different search terms has been summarized in Table [1](#Tab1){ref-type="table"}. The mean age of the subjects was 66.95 years with the proportion of male subjects ranging from 45^[@CR5]^ to 100%^[@CR21]^. On average, each subject had a 46 pack-year smoking history. The mean forced expiratory volume in one second (FEV~1~) ranged from 0.96 L to 1.62 L. A total of 21 studies explored the role of blood eosinophilia in COPD. The remaining articles detected eosinophils in sputum and bronchial fluid after treatment with bronchodilators or steroidal therapy. The description of studies is summarized in Table [2](#Tab2){ref-type="table"}. More than half of the included studies were either conducted in the United Kingdom^[@CR1],[@CR9]--[@CR11],[@CR13],[@CR17],[@CR18],[@CR22]--[@CR27]^ or other European countries^[@CR2]--[@CR4],[@CR21],[@CR28]--[@CR31]^. Eleven studies were originated from the Asia-Pacific region^[@CR5],[@CR6],[@CR32]--[@CR35]^ and the North America^[@CR19],[@CR20],[@CR36]--[@CR38]^. There was only a single relevant publication from the Middle East^[@CR12]^.Figure 1Flow diagram of literature search and selection of studies. Table 1Number of entries by different search terms.KeywordsPubMedISIEmBaseScopusEosinophil416561900253271---COPD668013662259900---COAD62620406650737Chronic Obstructive Pulmonary Disease62138365696458362441Chronic Obstructive Airway Disease6295791821681817754COPD OR COAD OR Chronic Obstructive Pulmonary Disease OR Chronic Obstructive Airway Disease68033532349131075056(Esosinophil) AND (COPD OR COAD OR Chronic Obstructive Pulmonary Disease OR Chronic Obstructive Airway Disease)6433321236920Total3131 Table 2Description of the included studies.First authorYearCountrySingle/Multi-centerNumber of subjectsStudy designMean age (Years)Male (%)Baseline FEV1Smoking (Pack-years)SpecimensEosinophil measurementBafadhel2009UKSingle34Longitudinal6882.436% Pred45SputumAbsolute and differential countBafadhel2011UKSingle145Longitudinal69701.33 L49Blood and SputumAbsolute and differential countBafadhel2012UKSingle164RCT6965.21.19 L54.5Blood and SputumAbsolute and differential countBafadhel2016UKMultiple243Prospective cohort71551.05 L49BloodAbsolute and differential countBalzano1999ItalySingle46Case-control66.310046.6% Pred≥1SputumDifferential count and ECP levelBarnes2016UKSingle751RCT63.8721.32 L43.2BloodAbsolute and differential countBathoorn2009The NetherlandsSingle45Longitudinal6481.663% Pred40Blood and SputumAbsolute and differential countBrightling2000UKSingle67RCT68591.1533SputumDifferential count and ECP levelCouilard2016USASingle167Retrospective cohort71.451.552.2% PredNABloodDifferential countBrightling2005UKSingle60RCT67661.2240Blood and SputumAbsolute and differential countD'Armiento2009USASingle148Case-control65.858.141.3% Pred57.8Lung larvage and plasmaLung lavage eotaxin-I levelDiSantostefano2016USAPopulation-based948Cross-sectional59.559.7≤70% Pred≥10BloodAbsolute and differential countDuman2015TurkeySingle1704Retrospective cohort7066.9≤70% PredNABloodAbsolute and differential countEltobili2014USASingle103Case-control66.566.95148Blood and SputumAbsolute and differential countFabbri2003ItalySingle46Case-control65.365.21.62 L35.8Sputum and bronchial biopsyDiffernetial count and histologyFijimoto1999JapanSingle24Prospective cohort6910040.5% Pred60SputumAbsolute and differential countFujimoto2005JapanSingle62Longitudinal nested case-control68.5941.40 L50.5SputumAbsolute and differential countGorska2008PolandSingle39Case-control56.858.873% Pred38.6SputumAbsolute and differential countHinds2016USAMultiple3255RCT6561≤70% Pred≥10BloodAbsolute and differential countHolland2010UKSingle65Retrospective cohort75.9NANANABloodDifferential countIqbal2015UKMultiple4647Retrospective cohort≥40NA≤70% Pred≥10BloodAbsolute and differential countKitaguchi2012JapanSingle63Case-control7290.547.5% Pred60.8SputumAbsolute and differential countLouis2002UKSingle49Case-control6173.354% Pred≥20SputumDifferential count and ECP levelMercer2005UKSingle19Longitudinal69851 LNASputumAbsolute and differential countNegewo2016AustraliaMultiple141Case-control69.86357.5% Pred37.5BloodAbsolute and differential countPapi2006ItalySingle64Longitudinal70.687.50.96 L48.3SputumAbsolute and differential countPark2016KoreaSingle130Prospective cohort6797.7≤80% Pred46BloodAbsolute and differential countPavord2016UKMultiple3045Retrospective cohort64.179≤70% Pred38BloodAbsolute and differential countPerng2006TaiwanSingle62RCT7298.41.27 L48SputumAbsolute and differential countPesci1998ItalySingle12Case-control62.691.771.1% Pred38.6Bronchial larvageDiffernetial count and ECP levelRahimi-rad2015IranSingle100Prospective cohort70.86937.27% PredNABloodDifferential countSalturk2015TurkeySingle647Retrospective cohort; Nested case-control6880.8NA41.5BloodDifferential countSerafino-Agrusa2016ItalySingle132Retrospective cohort; Nested case-control72.968.944.9% Pred70.3BloodAbsolute and differential countSiva2007UKSingle82RCT70671.02 L49.1Blood and SputumAbsolute and differential countSnoeck-Stroband2008The NetherlandsMultiple114Case-control6086.863% Pred41Sputum and bronchial biopsyAbsolute and differential countVedel-Krogh2016DenmarkPopulation-based81668Prospective cohort584578% Pred30BloodAbsolute and differential countZanini2015ItalySingle31Cross-sectional6779.368% Pred51SputumAbsolute and differential countKeys: ECP, eosinophil cationic protein; NA, not reported; Pred, predicted; RCT, Randomized controlled trial.

Overall, included studies fell into low to moderate quality (Supplementary Tables [1](#MOESM1){ref-type="media"} and [2](#MOESM1){ref-type="media"}). Of 24 non-randomized observational studies evaluated by Newcastle-Ottawa scale, the mean score was 4.5 out of nine (range: 2--6). Five studies scored six or above in a nine-point scale, indicating high study quality^[@CR6],[@CR7],[@CR11],[@CR22],[@CR30]^. In 13 randomized control trials assessed by Cochrane Collaboration Risk of Bias tool, seven studies were rated as low risk in terms of allocation concealment, blinding of participants and personnel, blinding of outcome assessment and incomplete outcome data^[@CR9]--[@CR11],[@CR20],[@CR24],[@CR26],[@CR27]^. Notably, two studies were ranked as high risk for randomization, blinding, and selective reporting^[@CR4],[@CR32]^.

Eight populations of six studies^[@CR5],[@CR7],[@CR13],[@CR16],[@CR19],[@CR20]^ were pooled for risk analysis. Overall, no association was observed between eosinophilia and risk for exacerbation warranting hospital admission in 12 months (OR = 1.07, 95% CI 0.86--1.32, *P* = 0.55, *I* ^2^ = 73%). This null effect remained in sub-group analysis of studies involving hospitalized COPD patients^[@CR13],[@CR16],[@CR19],[@CR20]^. Interestingly, in patients with stable COPD as defined as having no hospitalization in the previous 12 months, eosinophilia appears to increase the risk for exacerbation by 18% (OR = 1.18, 95% CI 1.03--1.34, *I* ^2^ = 0%) **(**Fig. [2](#Fig2){ref-type="fig"} **)**.Figure 2Forest plots of studies comparing the risk for exacerbation in 12 months in COPD patients with or without eosinophilia. Vedel-Krogh (2015) subgroup A, clinical COPD; Vedel-Krogh (2015) subgroup B, COPD cohort in general population; Pavord (2016) subgroup A, COPD patients on fluticasone propionate and salmeterol; Pavord (2016) subgroup B, COPD patients on fluticasone propionate.

Pooled estimate of five studies^[@CR12],[@CR14],[@CR16]--[@CR18]^ did not indicate an association between eosinophilia and in-hospital mortality, though approaching statistical significance (*P* = 0.08). Of note, a single largest study published in the Lancet^[@CR26]^ did not identify any association between clinical outcomes and eosinophilia. Although pooled estimate of the other studies^[@CR12],[@CR14],[@CR17],[@CR18]^ showed that eosinophilia was a protective factor against in-hospital mortality (OR = 0.38, 95% CI 0.17--0.86, *I* ^2^ = 35%), these studies have to be interpreted with cautions due to potential risk of bias. Patients with eosinophilic COPD had 1.2 days shorter hospital stay than non-eosinophilic individuals. Given moderate to high heterogeneity of overall estimates, sensitivity analysis was performed. Except for in-hospital mortality, no single study substantially altered the pooled estimates (Figs [3](#Fig3){ref-type="fig"} and [4](#Fig4){ref-type="fig"}).Figure 3Forest plots of studies comparing the risk for in-hospital mortality in COPD patients with or without eosinophilia. Figure 4Forest plots of studies comparing the mean difference of the length of hospital stay.

Subsequent to concurrent treatments with bronchodilators and steroids the pooled estimate revealed slight improvement in change of FEV1 (SMD = 0.52, 95% CI 0.33--0.71) (Fig. [5](#Fig5){ref-type="fig"}). Sub-group analysis has also shown that outpatients with eosinophilic COPD exhibited improvement in pulmonary function. For outpatient groups, the combined mean differences for FEV~1~ and percentage of predicted FEV~1~ were 0.11 L (95% CI 0.09--0.13, *P* \< 0.001) and 1.64% (95% CI 0.05--3.23, *P* \< 0.001), respectively (Figs [5](#Fig5){ref-type="fig"} and [6](#Fig6){ref-type="fig"}).Figure 5Forest plots of studies comparing the mean difference of the change of FEV1 in COPD patients after therapy. Bafadhel (2012) subgroup A, clinical outcomes in 2 weeks after therapy. Bafadhel (2012) subgroup B, clinical outcomes in 6 weeks after therapy. Figure 6Forest plots of studies comparing the mean difference of the change of % FEV1 predicted in COPD patients after therapy. Bafadhel (2012) subgroup A, clinical outcomes in 2 weeks after therapy. Bafadhel (2012) subgroup B, clinical outcomes in 6 weeks after therapy. Pavord (2016) subgroup A, COPD patients on fluticasone propionate and salmeterol; Pavord (2016) subgroup B, COPD patients on fluticasone propionate; Pavord (2016) subgroup C, COPD patients on salmeterol.

Of the three studies comparing reported QOL in patients with COPD, chronic respiratory disease questionnaire (CRQ)^[@CR9],[@CR10]^ and St George's respiratory questionnaire (SGRQ) were used^[@CR11]^. The eosinophilic group consistently reported a higher QOL score subsequent to therapy. For studies using CRQ, a standardized mean difference of 0.85 (95% CI 0.56--1.14) was observed. For studies using SGRQ, an improved quality of life was also reported (SMD = 3.14, 95% CI 2.93--3.36). The pooled analysis is presented in Fig. [7](#Fig7){ref-type="fig"}.Figure 7Forest plots of studies comparing the standardized mean difference of the change of quality of life scores in COPD patients after therapy. Pavord (2016) subgroup A, COPD patients on fluticasone propionate and salmeterol.

Discussion {#Sec3}
==========

Overall, eosinophilia in COPD patients does not contribute to exacerbation risk, in-hospital mortality, and length of hospital stay. However, higher eosinophil count in the outpatient sub-group demonstrated an increased risk of exacerbation by 18%. On the other hand, eosinophilic COPD patients appeared to be more responsive to therapeutic interventions.

In previous investigation of hospitalized COPD patients with severe exacerbation, eosinophilia lacked association with more than three-fold increased risk for re-admission in 12 months^[@CR19]^. Retrospective analysis of COPD population with a post-bronchodilator FEV~1~/forced vital capacity (FVC) ratio below 0.7 did not identify significant difference in exacerbation risk amongst the eosinophil dominant group^[@CR22]^. These were in contrast to a Turkish study in which a greater risk for re-admission was demonstrated in the eosinophilic group^[@CR16]^. In a Dutch general population study, eosinophilia was found to increase risk for acute exacerbation of COPD^[@CR7]^. Consistently, we found 18% increased risk for disease aggravation in outpatients. Exacerbation has been linked to airway inflammation characterized by eosinophilia^[@CR4],[@CR6],[@CR24]^ and imbalance of metalloproteinases^[@CR23]^. Higher level of eotaxin, an eosinophil chemotactic factor, is elevated in pulmonary lavage^[@CR37]^. It has been suggested that frequency and severity of COPD exacerbation was a result of impaired macrophage efferocytosis of eosinophils^[@CR36]^. Marked eosinophilia was observed in virus-induced exacerbations^[@CR30]^.

Our pooled analysis showed that eosinophilia is associated with reduced length of hospital stay. This is consistent with previous studies including severely exacerbated COPD patients^[@CR14],[@CR18]^. Conversely, peripheral blood eosinopenia increased in-hospital mortality by up to five-fold^[@CR12],[@CR17]^. The disparity may be attributable to the timing of blood specimen collection. For hospitalized patients, samples were collected at the time of admission^[@CR12],[@CR14],[@CR16]--[@CR18]^. The time for collection in the outpatient group varies across studies and included at the screening stage^[@CR11]^, at exacerbation^[@CR10]^, and at 24 h after bronchodilator therapy^[@CR9]^. In addition, recent hospitalization histories of these outpatients were uncertain^[@CR9]--[@CR11]^. In other words, they may have never been hospitalized or had follow-up at clinics soon after discharge. It has been suggested that airway eosinophilia facilitated responsiveness to bronchodilator and steroidal therapies^[@CR26],[@CR33]^. The better response to therapy in this patient population may explain the consistently shorter length of stay and lower mortality.

Eosinophilia has been suggested to indicate individual responsiveness to bronchodilator and steroidal therapies^[@CR9]--[@CR11],[@CR13],[@CR15],[@CR25],[@CR26],[@CR34]^. Post-hoc analysis confirmed that level of eosinophil correlates with the response to bronchodilators^[@CR27]^. Specifically, post-bronchodilator FEV~1~ and sputum eosinophil level had a high correlation of 0.82^[@CR31]^. After oral prednisolone therapy, sputum eosinophil count changed accordingly along with interleukin-5^[@CR25]^. Blood eosinophils were also found to be associated with changes in pulmonary function after inhaled corticosteroids^[@CR10],[@CR11],[@CR13],[@CR20]^. In our meta-analysis, although the predicted %FEV~1~ changed by 1.64%, this may represent a substantial improvement given these subjects were considered as severe COPD with baseline predicted %FEV~1~ less than 50%^[@CR9],[@CR10]^. However, the addition of hospitalized patients nullified the effect. This suggested that disease severity may be a significant confounder in the observed relationship.

The overall risk of bias in the included randomized control trials ranged from low to moderate. The inferior quality was mostly attributed to unclear sequence generation and likelihood of selective outcome reporting^[@CR4],[@CR32],[@CR34],[@CR35],[@CR37]^. Eight of the studies applied allocation concealment, and blinding of participants and outcome assessors^[@CR9]--[@CR11],[@CR18],[@CR20],[@CR24],[@CR27],[@CR35]^. In quasi-experimental studies, the potential risks of bias included self-reporting for outcomes, insufficient follow-up period and unclear relationship between loss of follow-up and outcome of interest. In addition, appropriate adjustments were not performed for previously reported confounders associated with eosinophil level and clinical outcome of COPD^[@CR38]^. The majority of the included population was originated from the United Kingdom and other European countries; only a few studies were conducted in the Continent of Asia and the America. This racially skewed population may preclude the generalizability of the evidence.

We performed this systematic review according to a pre-defined data abstraction form. Minor alterations were made to facilitate data pooling. There were missing data on some of the outcome measures of our interest, reducing the number of eligible studies. Given the limited number of included studies for each outcome comparison, neither funnel plot nor Doi plot were conducted to examine publication bias. Our sensitivity analysis revealed that, except for in-hospital mortality, the pooled estimates remained stable.

Given no consensus on definition of eosinophilia, there may be mixing of eosinophilic and non-eoinophilic groups of COPD patient, diluting the effect size. The estimation of eosinophil level varies with the type of specimens. Within the same patient group, bronchial biopsies yielded lower eosinophil count than induced sputum^[@CR29]^. Importantly, the temporal variation of eosinophilia in COPD was largely ignored in the included studies. Longitudinal study of 1,483 patients with COPD revealed that 49% of the subjects had variable eosinophil counts^[@CR39]^. Only 37% and 14% of the individuals were persistently eosinophilic and eosinopenic, respectively^[@CR39]^. The level of this cellular marker can increase considerably soon after sputum induction^[@CR40]^. In this connection, spotshot sampling may lead to misclassification of case and control.

The moderate to high heterogeneity of the pooled estimates suggests the presence of unknown confounders in association with eosinophilia and COPD. This may be attributed to a range of severity of COPD patients included in the studies and the timing of blood collection. Other potential confounding variables may include, but not limited to, specimen type, baseline characteristics of the study population, study quality and unknown pre-existing co-morbidities. Cross-sectional analysis of 948 COPD patients revealed that eosinophilic group was associated with lower rate of heart attack and anemia^[@CR38]^. If these contributed to different clinical outcome of this sub-group remained equivocal. The use of steroidal therapy may interfere with the risk for exacerbation. Given the lack of accessibility to information on individual exposure, it was impossible to control for the factor of steroidal therapy in the pooled estimate of exacerbation risk.

In conclusion, eosinophilia is associated with a better improvement of pulmonary function and reported QOL subsequent to therapy in outpatients. Given its association with eosinophil level in the airway, blood eosinophil count may be a predictive biomarker in patients with stable COPD for response to steroidal and bronchodilator therapies.

Methods {#Sec4}
=======

Searching strategy {#Sec5}
------------------

This systematic review was performed in accordance with the guidelines on Preferred Reporting Items for Systematic Reviews and Meta-analyses: The PRISMA Statement 2009^[@CR41]^. Original articles published in PubMed (MEDLINE), ISI Web of Knowledge, EMBASE, and Scopus database were identified using Medical Subject Heading (MeSH) or Title/ Abstract keywords from inception up to December 2016. The MeSH search terms include a combination of eosinophil, blood, sputum, pulmonary disease, chronic obstructive, and/or airway disease. The number of entries retrieved from each database is summarized in Fig. [1](#Fig1){ref-type="fig"}. Two authors (JH and WH) performed the literature search and selected the relevant studies independently. Disagreements in terms of study selection were resolved by discussion with senior authors.

Inclusion and exclusion criteria {#Sec6}
--------------------------------

Included studies were primary research articles comparing patients with and without eosinophilic COPD in terms of exacerbation risk, mortality, morbidity, length of hospital stay, and response to corticosteroids and bronchodilators. Quasi-experimental studies and randomized controlled trials were included. Pre-clinical studies, review articles, editorials, commentaries, conference abstracts and book chapters were excluded.

Data extraction {#Sec7}
---------------

Relevant data were extracted according to a pre-defined data abstraction form. Information on sample size, baseline characteristics, incidence of exacerbation in the past 12 months, length of hospital stay, in-hospital mortality, QOL, and pulmonary function were extracted by one researcher (JH) and verified by a second researcher (WH).

Quality assessment and statistical analysis {#Sec8}
-------------------------------------------

The methodological quality of the included randomized controlled trials and quasi-experimental studies was evaluated by the Cochrane Risk of Bias Tool^[@CR42]^ and the Newcastle-Ottawa scale^[@CR43]^ respectively. The former tool indicates studies with high, low or unclear risk according to five domains: selection bias, performance bias, detection bias, attrition bias, and reporting bias. The latter scale evaluates the quality of studies in three attributes, namely selection of cohort, comparability, and outcome. In this review, a high-quality study is defined as having \>6 points whereas a low-quality study as having ≤5 points.

Meta-analysis compared patients with eosinophilic and non-eosinophilic COPD in terms of exacerbation risk, length of hospital stay, in-hospital mortality, and change of pulmonary function and QOL in response to medical interventions. Heterogeneity across studies was determined by the *I* ^2^ statistic using Cochrane Review Manager 5.3^[@CR44]^. An *I* ^2^ values ≥ 25, 50 and 75% were considered as mild, moderate, and high degree of heterogeneity, respectively. For pooled outcome measures with *I* ^2^ \> 50%, a random-effect model was used to evaluate the overall effect of a given comparison. Studies were weighted by inverse of variance. Categorical data was presented as odds ratio (OR) in 95% confidence interval (CI). For continuous variables, the pooled estimates were compared by mean difference (MD) or standardized mean difference (SMD), as appropriate. In the occasion when the remaining studies appeared to be different from the overall estimate, sub-group analysis was performed.
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